Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019

Clinical Infectious Diseases(2020)10.1093/cid/ciaa453Source: DataRank Database

Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019 is a research paper published in Clinical Infectious Diseases (2020). On theSindex it has a DataRank of 0. It has been cited 99 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access99 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.27)OA: hybridTopics (35)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

David L. Thomas ORCID,Sarah S. Jackson ORCID,Ludmila Prokunina‐Olsson ORCID,Raymond P. Donnelly ORCID,Rune Hartmann ORCID

Live enrichment

PubMed:32301957 PMC:PMC7184357 OpenAlex:https://openalex.org/W3016467573

Novo Nordisk Fonden

Grant: NNF19OC0058287

Division of Cancer Epidemiology and Genetics, National Cancer Institute

National Institutes of Health

FWCI

2.27

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

hybridLicense: public-domain

journalhttps://academic.oup.com/cid/article-pdf/71/6/1410/33738614/ciaa453.pdf

publisherhttps://academic.oup.com/cid/article-pdf/71/6/1410/33738614/ciaa453.pdf

publisherhttp://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa453/33431622/ciaa453.pdf

publisherhttp://academic.oup.com/cid/article-pdf/71/6/1410/33738614/ciaa453.pdf

journalhttps://doi.org/10.1093/cid/ciaa453

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesHepatitis C virus research

MeSH Terms

BetacoronavirusCOVID-19SARS-CoV-2COVID-19 Drug TreatmentHumansImmunity, InnateInterferon-gammaInterferonsLungPneumonia, ViralVirus ReplicationCoronavirus InfectionsPandemics

Keywords

MedicineInterferonCoronavirusCoronavirus disease 2019 (COVID-19)VirologyImmunologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BetacoronavirusDisease2019-20 coronavirus outbreakRespiratory diseaseInternal medicineInfectious disease (medical specialty)OutbreakLungSARS-Covsevere acute respiratory syndromeinnate immunityMers-cov

Sustainable Development Goals

SDG 0: Good health and well-being

Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019

FAIR Checklist

Authors (6)

Funding (3 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)